Analysts Issue Forecasts for VKTX Q4 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at HC Wainwright issued their Q4 2026 earnings estimates for Viking Therapeutics in a note issued to investors on Thursday, February 12th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same quarter last year, the business posted ($0.32) EPS.

Other analysts have also recently issued research reports about the company. Zacks Research cut Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald set a $105.00 price target on shares of Viking Therapeutics in a research note on Thursday, October 23rd. B. Riley Financial raised shares of Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a report on Friday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.80.

Viking Therapeutics Price Performance

Shares of VKTX opened at $29.00 on Friday. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $43.15. The stock has a market cap of $3.35 billion, a PE ratio of -9.12 and a beta of 0.75. The firm has a fifty day moving average price of $33.13 and a 200 day moving average price of $32.58.

Insider Activity

In other Viking Therapeutics news, COO Marianna Mancini sold 57,661 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $32.98, for a total value of $1,901,659.78. Following the sale, the chief operating officer owned 409,190 shares of the company’s stock, valued at approximately $13,495,086.20. The trade was a 12.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian Lian sold 233,409 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $32.96, for a total value of $7,693,160.64. Following the transaction, the chief executive officer directly owned 2,499,291 shares of the company’s stock, valued at approximately $82,376,631.36. This trade represents a 8.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 364,731 shares of company stock valued at $12,053,627. 4.10% of the stock is owned by insiders.

Institutional Trading of Viking Therapeutics

Institutional investors have recently modified their holdings of the business. Jump Financial LLC acquired a new position in Viking Therapeutics during the second quarter worth about $12,201,000. Norges Bank acquired a new stake in shares of Viking Therapeutics during the 2nd quarter valued at approximately $46,846,000. RFG Advisory LLC boosted its stake in shares of Viking Therapeutics by 84.8% during the 3rd quarter. RFG Advisory LLC now owns 120,214 shares of the biotechnology company’s stock worth $3,159,000 after acquiring an additional 55,175 shares in the last quarter. Marex Group plc acquired a new stake in shares of Viking Therapeutics in the 2nd quarter worth approximately $983,000. Finally, Bryce Point Capital LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter worth approximately $499,000. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Viking Therapeutics

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Company fast‑tracked oral VK2735 into Phase III obesity trials, a material clinical de‑risking and commercialization signal that prompted a sharp rally in headlines and investor enthusiasm. Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed?
• Positive Sentiment: Management outlined dual Phase III obesity programs and maintenance regimens for VK2735, giving investors a clearer late‑stage development plan and multiple potential commercialization paths. Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
• Neutral Sentiment: Coverage and valuation checks are proliferating (analysis pieces and retrospectives on historical returns), which can broaden investor interest but don’t change clinical or financial fundamentals. Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress
• Neutral Sentiment: Media and transcript coverage (earnings call transcripts, long‑term return pieces) are available for deeper diligence but are informational rather than new catalysts. Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results showed a wider‑than‑expected loss (EPS miss) which raises near‑term cash‑burn and financing questions; that financial disappointment likely prompted profit‑taking after the clinical rally. VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
• Negative Sentiment: Analysts (HC Wainwright) continue to model losses for upcoming quarters/years, reinforcing the expectation that Viking will need to fund late‑stage development — a potential dilution risk that can cap upside until Phase III readouts or financing clarity. MarketBeat VKTX overview / analyst note

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.